Board of Directors
Chair, Board of Directors, Ribon Therapeutics
Jodie Morrison has served as chairman and a member of our board of directors since July 2020. Ms. Morrison is an accomplished executive and board member with experience from start up through mid-size public biotech and pharmaceuticals. Her most recent operating role was Chief Executive Officer of Cadent Therapeutics where she led the growth of the company from early-stage clinical trials through the successful acquisition by Novartis in 2021. Prior to Cadent, Ms. Morrison served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. (leading the successful merger with Akebia Therapeutics) and Acting Chief Operating Officer at Syntimmune (acquired by Alexion). Prior to Syntimmune she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. (led IPO in 2014 and merger in 2016) and held other senior positions including Chief Operating Officer and VP/Head of Clinical and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Aileron Therapeutics (ALRN). She previously served on the Cadent board and the pre/post-merger boards for Keryx/Akebia Biopharmaceuticals and Tokai/Novus Pharmaceuticals. Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.
James Audia, Ph.D.
Executive Director, Chicago Biomedical Consortium
James Audia, Ph.D. has served as a member of our board of directors since April 2018. Dr. Audia is the chairman of our scientific advisory board. Dr. Audia is the president and sole proprietor of Audia Consulting, LLC, a scientific consulting firm which he founded in September 2019. Since November 2019, Dr. Audia has served as an entrepreneur in residence for Third Rock Ventures, a venture capital firm, and as the head of medicinal chemistry and senior advisor for Karuna Therapeutics, Inc. Dr. Audia has been an advisor to the Alzheimer’s Association since January 2020. Dr. Audia served as executive director of the Chicago Biomedical Consortium, or CBC, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation, from August 2017 to October 2019 and retains a visiting scholar appointment at Northwestern University. Prior to joining the CBC, Dr. Audia served as the chief scientific officer of Constellation Pharmaceuticals, Inc. from January 2011 to July 2017. Dr. Audia served in various roles at Eli Lilly & Company from 1987 until December 2010. Dr. Audia serves on the board of directors of Constellation Pharmaceuticals, Inc. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University.
Laura Brass, Ph.D., M.B.A.
Managing Director, Novartis Venture Fund
Laura Brass, Ph.D., M.B.A. has served as a member of our board of directors since April 2021. Dr. Brass is a Managing Director at NVF in Cambridge, MA, USA. Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics of live patient data for clinical research. Laura has also held roles in business development and IP strategy at Elixir Pharmaceuticals, and was CEO of Aferon, Inc., an early-stage antiviral start-up company. Laura holds a B.A. in Philosophy and a B.S. in Biochemistry from the University of Missouri-Columbia, and a Ph.D. in Molecular Genetics and Cell Biology and an M.B.A. from the University of Chicago.
CFO, Constellation Pharmaceuticals
Emma Reeve has served as a member of our board of directors since October 2020. Ms. Reeve has served as senior vice president and chief financial officer of Constellation since October 2017 and treasurer of Constellation since December 2017. Ms. Reeve served as corporate controller of PAREXEL International Corporation, or PAREXEL, a life sciences consulting firm and contract research organization, from September 2014 to October 2017 and as interim chief financial officer and corporate controller of PAREXEL from July 2016 to May 2017. Ms. Reeve served as head of finance and administration at Novartis Pharma Schweiz, a pharmaceutical company, from May 2012 to August 2014 and as vice president, global head business planning and analysis for Novartis Vaccines and Diagnostics, a division of Novartis AG, a healthcare company, from January 2008 to April 2012. She served as chief financial officer of Inotek Pharmaceuticals Inc., a biotechnology company, from 2006 to 2007, as senior director of research operations at Merck Research Laboratories, a pharmaceutical company, from 2004 to 2006 and as chief financial officer of Aton Pharma, Inc., a biotechnology company, from 2002 to 2004. Ms. Reeve also worked at Bristol-Myers Squibb Company, a biopharmaceutical company, from 1994 to 2002. Ms. Reeve serves on the board of directors of PTC Therapeutics, Inc., a public biopharmaceutical company. Ms. Reeve is an associate of the Institute of Chartered Accountants in England & Wales. Ms. Reeve received a B.Sc. in computer science from Imperial College, University of London.
Victoria Richon, Ph.D.
President and CEO, Ribon Therapeutics
Victoria Richon, Ph.D. has served as our president and as a member of our board of directors since the founding of our company in November 2015 and has served as our chief executive officer since January 2017. Prior to becoming our chief executive officer, she served as our chief scientific officer from November 2015 to January 2017. Prior to joining us, Dr. Richon served as vice president, global head of oncology research and translational medicine at Sanofi Oncology from November 2012 to October 2015. Dr. Richon served as the vice president of biological sciences at Epizyme, Inc. from October 2008 to November 2012. Dr. Richon served as the senior director and head of the Cancer Biology and Therapeutics Department at Merck & Co. from 2004 to 2008. Dr. Richon serves on the board of directors of Epizyme, Inc and HotSpot Therapeutics, Inc. Dr. Richon received a B.A. in chemistry from the University of Vermont and a Ph.D. in biochemistry from the University of Nebraska Medical Center.
Jonathan Root, M.D.
General Partner, US Venture Partners
Jonathan Root, M.D. has served as a member of our board of directors since November 2015. Dr. Root has served as a managing member of Presidio Management Group XI, L.L.C., the general partner of U.S. Venture Partners XI, L.P., and of the several general partnerships for the other U.S. Venture Partners’ venture capital funds, since 1998. Dr. Root currently serves on the board of directors of Inari Medical, Inc. (NARI) and several private companies in the healthcare industry. Dr. Root served on the board of directors of OncoMed Pharmaceuticals, Inc. from August 2004 until its merger with Mereo BioPharma Group plc in April 2019. Dr. Root received an A.B. in economics from Dartmouth College, an M.D. from University of Florida, College of Medicine and an M.B.A. from Columbia Business School.
Peter Svennilson, M.B.A.
Managing Partner and Founder, The Column Group
Peter Svennilson has served as a member of our board of directors since September 2019. Mr. Svennilson also previously served as a member of our board of directors from October 2017 to April 2019. Mr. Svennilson serves as a managing partner of The Column Group, a biotechnology venture capital firm which he founded in February 2007. Mr. Svennilson served as the president and chief executive officer at ORIC Pharmaceuticals, Inc. from June 2015 to November 2015. Prior to founding The Column Group, he founded Three Crowns Capital, where he served as its managing partner from June 1996 to February 2007. Mr. Svennilson serves on the board of directors of ORIC. Mr. Svennilson previously served on the boards of directors of NGM Biopharmaceuticals, Inc. from January 2008 to May 2020, Gristone Oncology, Inc. from September 2015 to September 2019, Constellation Pharmaceuticals, Inc. from June 2016 to June 2019 and Immune Design Corp. from 2014 to August 2018. Mr. Svennilson is currently a trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received a B.S. and M.B.A. from the Stockholm School of Economics and Finance.
Cameron Wheeler, Ph.D.
Partner, Deerfield Management
Cameron Wheeler, Ph.D. has served as a member of our board of directors since February 2016. Dr. Wheeler has served as a partner at Deerfield Management Company, L.P., or Deerfield, a healthcare investment firm, since December 2018, and previously served as a principal at Deerfield beginning in September 2014. Prior to joining Deerfield, Dr. Wheeler was at Eleven Biotherapeutics, Inc. (now Sesen Bio, Inc.), where he was responsible for corporate development and commercial strategy. Dr. Wheeler previously served on the board of directors of Homology Medicines, Inc. from March 2018 to July 2019. Dr. Wheeler received a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.